Studieoverzicht
Study name: REGN7075: COMBINE-EGFR-1 (COstiM BIspecifics for the treatment of NEoplasia)
| Histology | NSCLC, all subtypes, Other | ||
|---|---|---|---|
| Tumor stage | Stage III - IV | ||
| Host / recruiting site 1 | Erasmus MC | Enrollment | Recruiting |
| Host / recruiting site 2 | Antoni van Leeuwenhoek | Enrollment | Recruiting |
| Therapy line | Later line (≥2L) | ||
| Design |
A PHASE 1/2 STUDY OF REGN7075 (EGFRxCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS. |
||
| Intervention | REGN7075 (EGFRxCD28 COSTIMULATORY BISPECIFIC ANTIBODY) +/- Cemiplimab |
||
| Key inclusion criteria | Cohort G: EGFR-Mutant NSCLC Post 3rd Generation TKI
|
||
| Key exclusion criteria |
|
||
| Contact information | Log in voor de contactinformatie | ||

